Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heptares-Powered Sosei's Incoming CEO Explains What Happens Next

Executive Summary

Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.

You may also be interested in...



Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion

Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.

Sosei Names New CEO

Japanese biopharma Sosei Group Corporation has appointed Peter Bains representative executive officer and CEO, taking over from founder Shinichi Tamura, who has been appointed representative executive officer and executive chair. Bains joins the company from Syngene International Ltd., where he was executive director and CEO. Prior to this, he held leadership positions at several businesses, including Heptares Therapeutics Ltd and GlaxoSmithKline PLC. (Also see "Heptares-Powered Sosei's Incoming CEO Explains What Happens Next" - Scrip, 28 Apr, 2016.)

Kymab, Heptares Enter GPCR Targeting Pact

Two of Britain's leading science innovators – Mab specialist Kymab Ltd. and GPCR-targeting Heptares Therapeutics – are joining forces to discover, develop and commercialize new antibody drugs targeting a number of G protein-coupled receptors, focusing initially on immuno-oncology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel